Antisense Oligonucleotide

PASADENA, Calif., April 28, 2026 AcuraStem has received $7.5 million in grant funding from the California Institute for Regenerative...

LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...

Boston, Massachusetts, USA, April 6, 2026 Breakthrough Results in Rare Pediatric Epilepsy In a major advancement for precision neuroscience...

London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...

CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...

CAMBRIDGE, Mass., Feb. 23, 2026 — QurAlis announced interim clinical results from its Phase 1/2 ANQUR study demonstrating that...